NL
GSK icon

NVWM LLC’s GSK GSK Stock Holding History

NVWM LLC’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,371
Closed -$408K – 469
2023
Q1 		$408K Sell
11,371
-159
-1% -$5.56K 0.14% 178
2022
Q4 		$409K Buy
11,530
+73
+0.6% +$2.43K 0.15% 160
2022
Q3 		$341K Buy
11,457
+2,150
+23% +$81.5K 0.14% 165
2022
Q2 		$511K Buy
9,307
+28
+0.3% +$1.55K 0.2% 146
2022
Q1 		$512K Buy
9,279
+9,199
+11,499% +$500K 0.16% 166
2021
Q4 		$4K Hold
80
– – ﹤0.01% 442
2021
Q3 		$4K Buy
80
+40
+100% +$2.01K ﹤0.01% 433
2021
Q2 		$2K Buy
+40
New +$1.92K ﹤0.01% 410
2020
Q4 		– Sell
-8,876
Closed -$408K – 379
2020
Q3 		$417K Buy
8,876
+7,036
+382% +$353K 0.2% 128
2020
Q2 		$95K Hold
1,840
– – 0.05% 155
2020
Q1 		$89K Hold
1,840
– – 0.06% 151
2019
Q4 		$108K Hold
1,840
– – 0.06% 153
2019
Q3 		$98K Buy
+1,840
New +$94.7K 0.06% 167

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NVWM LLC's GSK Position: Q2 2023 in Review

NVWM LLC sold out of GSK (GSK) in Q2 2023, closing a stake of 11,371 shares — an estimated $408K sold.

NVWM LLC first reported a position in GSK in Q3 2019 and held it in 13 quarters. The position peaked at $512K in Q1 2022. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

  • NVWM LLC reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
  • NVWM LLC sold 11,371 GSK shares in Q2 2023, an estimated $408K.
  • NVWM LLC first reported a position in GSK in Q3 2019 and held it in 13 quarters.
  • NVWM LLC's GSK position peaked at $512K in Q1 2022.
  • 827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on NVWM LLC's 13F filing for Q2 2023, filed 8 Aug 2023.